Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression.

Ding K, Shen J, Hafiz Z, Hackett SF, Silva RLE, Khan M, Lorenc VE, Chen D, Chadha R, Zhang M, Van Everen S, Buss N, Fiscella M, Danos O, Campochiaro PA.

J Clin Invest. 2019 Aug 13;130. pii: 129085. doi: 10.1172/JCI129085.

2.

Direct and indirect effects of a common cyanobacterial toxin on amphibian-trematode dynamics.

Buss N, Wersebe M, Hua J.

Chemosphere. 2019 Apr;220:731-737. doi: 10.1016/j.chemosphere.2018.12.160. Epub 2018 Dec 26.

PMID:
30611071
3.

Monoclonal antibody targeting of fibroblast growth factor receptor 1c causes cardiac valvulopathy in rats.

Buss N, Lapointe JM, de Haan L, Price S, Ahnmark A, Irving L, Buchanan A, Keyes F, Davidsson P, Dixit R, Lindén D.

Toxicol Appl Pharmacol. 2018 Sep 15;355:147-155. doi: 10.1016/j.taap.2018.06.033. Epub 2018 Jul 2.

PMID:
30008375
4.

Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension.

Buss N, Ryan P, Baughman T, Roy D, Patterson C, Gordon C, Dixit R.

J Appl Toxicol. 2018 Oct;38(10):1293-1301. doi: 10.1002/jat.3640. Epub 2018 May 28.

PMID:
29806696
5.

Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Oberst MD, Augé C, Morris C, Kentner S, Mulgrew K, McGlinchey K, Hair J, Hanabuchi S, Du Q, Damschroder M, Feng H, Eck S, Buss N, de Haan L, Pierce AJ, Park H, Sylwester A, Axthelm MK, Picker L, Morris NP, Weinberg A, Hammond SA.

Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15.

6.

Parasite susceptibility in an amphibian host is modified by salinization and predators.

Buss N, Hua J.

Environ Pollut. 2018 May;236:754-763. doi: 10.1016/j.envpol.2018.01.060.

PMID:
29455088
7.

Population-specific toxicity of six insecticides to the trematode Echinoparyphium sp.

Hua J, Buss N, Kim J, Orlofske SA, Hoverman JT.

Parasitology. 2016 Apr;143(5):542-50. doi: 10.1017/S0031182015001894. Epub 2016 Mar 1.

PMID:
26928351
8.

Targeting the annexin 1-formyl peptide receptor 2/ALX pathway affords protection against bacterial LPS-induced pathologic changes in the murine adrenal cortex.

Buss NA, Gavins FN, Cover PO, Terron A, Buckingham JC.

FASEB J. 2015 Jul;29(7):2930-42. doi: 10.1096/fj.14-268375. Epub 2015 Mar 27.

PMID:
25818588
9.

Modification of the postrotary nystagmus test for evaluating young children.

Mailloux Z, Leão M, Becerra TA, Mori AB, Soechting E, Roley SS, Buss N, Cermak SA.

Am J Occup Ther. 2014 Sep-Oct;68(5):514-21. doi: 10.5014/ajot.2014.011031.

PMID:
25184463
10.

Warfarin for stroke prevention following anterior ST-elevation myocardial infarction.

Buss NI, Friedman SE, Andrus BW, DeVries JT.

Coron Artery Dis. 2013 Dec;24(8):636-41. doi: 10.1097/MCA.0000000000000032.

PMID:
23974463
11.

Leukocyte recruitment in the brain in sepsis: involvement of the annexin 1-FPR2/ALX anti-inflammatory system.

Gavins FN, Hughes EL, Buss NA, Holloway PM, Getting SJ, Buckingham JC.

FASEB J. 2012 Dec;26(12):4977-89. doi: 10.1096/fj.12-205971. Epub 2012 Sep 10.

PMID:
22964301
12.

Monoclonal antibody therapeutics: history and future.

Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L.

Curr Opin Pharmacol. 2012 Oct;12(5):615-22. doi: 10.1016/j.coph.2012.08.001. Epub 2012 Aug 21. Review.

PMID:
22920732
13.

Annexin A1 and the formyl peptide receptor family: neuroendocrine and metabolic aspects.

John CD, Gavins FN, Buss NA, Cover PO, Buckingham JC.

Curr Opin Pharmacol. 2008 Dec;8(6):765-76. doi: 10.1016/j.coph.2008.09.005. Epub 2008 Oct 24. Review.

PMID:
18845272
14.

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.

Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP.

AIDS Patient Care STDS. 2007 Aug;21(8):533-43.

PMID:
17711378
15.

Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective.

Mayers DL, Chung J, Kohlbrenner VM, Hall DB, DeMasi RA, Neubacher D, Buss NE, Salgo MP.

AIDS Res Hum Retroviruses. 2006 Nov;22(11):1110-2. No abstract available.

PMID:
17147497
16.

Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).

Boyd MA, Dixit NM, Siangphoe U, Buss NE, Salgo MP, Lange JM, Phanuphak P, Cooper DA, Perelson AS, Ruxrungtham K.

J Infect Dis. 2006 Nov 1;194(9):1319-22. Epub 2006 Sep 25.

PMID:
17041859
17.

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.

Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12.

PMID:
16280694
18.

Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.

Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH.

Clin Pharmacol Ther. 2005 Jun;77(6):515-28.

PMID:
15961983
19.

Proteome of H-411E (liver) cells exposed to insulin and tumor necrosis factor-alpha: analysis of proteins involved in insulin resistance.

Solomon SS, Buss N, Shull J, Monnier S, Majumdar G, Wu J, Gerling IC.

J Lab Clin Med. 2005 May;145(5):275-83.

PMID:
15902099
20.

Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide.

Patel IH, Zhang X, Nieforth K, Salgo M, Buss N.

Clin Pharmacokinet. 2005;44(2):175-86. Review.

PMID:
15656696
21.

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.

Ruxrungtham K, Boyd M, Bellibas SE, Zhang X, Dorr A, Kolis S, Kinchelow T, Buss N, Patel IH.

J Clin Pharmacol. 2004 Jul;44(7):793-803.

PMID:
15199084
22.

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.

Boyd MA, Zhang X, Dorr A, Ruxrungtham K, Kolis S, Nieforth K, Kinchelow T, Buss N, Patel IH.

J Clin Pharmacol. 2003 Dec;43(12):1382-91.

PMID:
14615475
23.

Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV.

Moyle GJ, Buss NE, Goggin T, Snell P, Higgs C, Hawkins DA.

Br J Clin Pharmacol. 2002 Aug;54(2):178-82.

24.

Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy.

Moyle GJ, Buss NE, Gazzard BG.

J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):460-2. No abstract available.

PMID:
12138355
26.
27.

Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.

Kline MW, Brundage RC, Fletcher CV, Schwarzwald H, Calles NR, Buss NE, Snell P, DeLora P, Eason M, Jorga K, Craig C, Duff F.

Pediatr Infect Dis J. 2001 Jul;20(7):666-71.

PMID:
11465838
28.

Measuring the effectiveness of antiretroviral agents.

Buss N, Cammack N.

Antivir Ther. 2001 Mar;6(1):1-7. Review.

PMID:
11417758
29.

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.

Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N, Saag MS.

Antimicrob Agents Chemother. 2000 Oct;44(10):2672-8.

30.

Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.

Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N.

Br J Clin Pharmacol. 2000 Aug;50(2):99-107.

31.

Effect of ritonavir on saquinavir metabolism.

Buss N.

JAMA. 2000 Jun 14;283(22):2936-7. No abstract available.

PMID:
10865269
32.

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

Gieschke R, Fotteler B, Buss N, Steimer JL.

Clin Pharmacokinet. 1999 Jul;37(1):75-86.

PMID:
10451784
33.

Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy.

Moyle GJ, Sadler M, Buss N.

Clin Infect Dis. 1999 Feb;28(2):403-4. No abstract available.

PMID:
10064262
34.
35.

All-trans-retinoic acid in maternal plasma and teratogenicity in rats and rabbits.

Tembe EA, Honeywell R, Buss NE, Renwick AG.

Toxicol Appl Pharmacol. 1996 Dec;141(2):456-72.

PMID:
8975771
36.

The teratogenic metabolites of vitamin A in women following supplements and liver.

Buss NE, Tembe EA, Prendergast BD, Renwick AG, George CF.

Hum Exp Toxicol. 1994 Jan;13(1):33-43.

PMID:
8198828
37.

Blood pressure changes and sympathetic function in rats given cyclohexylamine by intravenous infusion.

Buss NE, Renwick AG.

Toxicol Appl Pharmacol. 1992 Aug;115(2):211-5.

PMID:
1641854
38.

Oxidative and non-oxidative metabolism of ethanol by the rabbit lung.

Manautou JE, Buss NJ, Carlson GP.

Toxicol Lett. 1992 Aug;62(1):93-9.

PMID:
1509512
39.

The metabolism of cyclamate to cyclohexylamine and its cardiovascular consequences in human volunteers.

Buss NE, Renwick AG, Donaldson KM, George CF.

Toxicol Appl Pharmacol. 1992 Aug;115(2):199-210.

PMID:
1379387

Supplemental Content

Support Center